2025.Dec.18
Corporate
OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation
TAIPEI, Taiwan, 12/18 – OBI Pharma (4174.TWO) today held its 2025 Investors’ Meeting, briefing investors on ADC R&D progress, financial planning, clinical development updates, and business development strategy, and outlining future directions.
This article is password protected.
To view the content, please enter your password in the field below